American Journal of Obstetrics & Gynecology
Volume 184, Issue 4 , Pages 598-602 , March 2001

Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis

Received 25 July 2000 ,Revised 22 August 2000 ,Accepted 28 September 2000.

References 

  1. Fong IW. Clinical and cost considerations in the pharmacotherapy of vulvovaginal candidiasis. Pharmacoeconomics. 1996;9:497–505
  2. Centers for Disease Control. Non-reported sexually transmitted diseases. MMWR Morb Mortal Wkly Rep. 1979;28:61–62
  3. Hurley R, De Louvois J. Candida vaginitis. Postgrad Med J. 1979;55:645–647
  4. Hurley R. Recurrent Candida infection. Clin Obstet Gynecol. 1981;8:209–213
  5. Spinillo A, Pizzoli G, Colonna L, Nicola S, De Seta F, Guaschino S. Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal candidiasis. Obstet Gynecol. 1993;81(5 Pt 1):721–727
  6. Sparks JM. Vaginitis. J Reprod Med. 1991;36:745–752
  7. Fidel PL, Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev. 1996;9:335–348
  8. Sobel JD. Recurrent vulvovaginal candidiasis: a prospective study of the efficacy of maintenance ketonazole therapy. N Engl J Med. 1986;315:1455–1458
  9. Sobel JD. Fluconazole maintenance therapy in recurrent vulvovaginal candidiasis. Int J Gynaecol Obstet. 1992;37(Suppl 1):17–24
  10. Spinillo A, Colonna L, Piazzi G, Baltaro F, Monaco A, Ferrari A. Managing recurrent vulvovaginal candidiasis: intermittent prevention with itraconazole. J Reprod Med. 1997;42:83–87
  11. Creatsas GC, Charalambidis VM, Zagtzidou EH, Anthopoulou HN, Michailidis DC, Aravantinos DI. Chronic or recurrent vaginal candidosis: short-term treatment and prophylaxis with itraconazole. Clin Ther. 1993;15:662–671
  12. Sobel JD, Chaim WE. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis. 1997;24:649–652
  13. Van Slyke KK, Michel VP, Rein MF. Treatment of vulvovaginal candidiasis with boric acid powder. Am J Obstet Gynecol. 1981;141:145–148
  14. Jovanovic R, Congema E, Nguyen HT. Antifungal agents vs boric acid for treating chronic mycotic vulvovaginitis. J Reprod Med. 1991;36:593–597
  15. Swate TE, Weed JC. Boric acid treatment of vulvovaginal candidiasis. Obstet Gynecol. 1974;43:893–895
  16. Nyirjesy P, Seeney SM, Grody MH, Jordan CA, Buckley HR. Chronic fungal vaginitis: the value of cultures. Am J Obstet Gynecol. 1995;173(3 Pt 1):820–823
  17. Redondo Lopez V, Lynch M, Schmitt C, Cook R, Sobel JD. Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstet Gynecol. 1990;76:651–655
  18. Shinohara YT, Tasker SA. Successful use of boric acid to control azole-refractory Candida vaginitis in women with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:219–220

☆ Reprint requests: Francesco De Seta, MD, Department of Obstetrics and Gynecology, University of Trieste, I.R.C.C.S. Burlo Garofolo, Via dell’Istria 65/1, 34100 Trieste, Italy.

PII: S0002-9378(01)33774-2

doi: 10.1067/mob.2001.111938

American Journal of Obstetrics & Gynecology
Volume 184, Issue 4 , Pages 598-602 , March 2001

Article Tools